PsiOxus Therapeutics updates agreement with Bristol-Myers Squibb to advance their clinical stage immuno-oncology collaboration

PsiOxus announced, today, an updated agreement to advance its clinical collaboration with Bristol Myers Squibb to evaluate the safety, tolerability, and preliminary efficacy of PsiOxus’ tumor re-engineering platform, in combination with Bristol Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo® (nivolumab) to treat a range of tumor types in late-stage cancer patients.

The first stage of this collaboration combined Bristol Myers Squibb’s Opdivo with PsiOxus’ enadenotucirev in the Phase 1 SPICE study to determine the safety and tolerability of combining these two agents, and to optimise the combination intravenous dosing regimen. The revised collaboration announced today will build upon the initial study data and will combine Opdivo with PsiOxus’ NG-641.

Download Press Release Here